Sanofi's stock experienced significant selling pressure Thursday and Friday following the announcement of a leadership transition at the pharmaceutical company. Chief Executive Officer Paul Hudson will step down on February 17, with Belén Garijo assuming the role following the company's April 29 annual general meeting. The shares declined 4.5% on Thursday and extended losses in premarket trading Friday, bringing the stock closer to its 52-week low of $44.62.
The executive transition occurs during a challenging period for the French pharmaceutical giant. The company faces headwinds including a 2.5% decline in vaccine sales and investor concerns regarding Dupixent's exclusivity cliff, which could pressure revenues once patent protection expires. However, the immunology flagship demonstrated resilience with 32.2% sales growth in the fourth quarter of 2025, providing some offset to broader pipeline concerns.
Despite the recent stock decline of 12.89% over the past year, the equity remains supported by analyst conviction. The consensus maintains a Buy rating with a $61.50 price target, suggesting analysts view the current valuation as attractive. The upcoming leadership transition and execution on pipeline initiatives will likely serve as key catalysts for investor sentiment in coming quarters.